Biomarin Pharma

NAGLAZYME

Manufacturer:

Biomarin Pharma

Naglazyme HCPCS:

J1458

HCPCS Code Descriptor:

Injection, galsulfase, 1 mg

Category:

J Code

Naglazyme NDCs:

68135-0020-01

Primary Type:

Enzyme Replacement Therapy

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Naglazyme:

NAGLAZYME is an Enzyme Replacement Therapy drug manufactured by Biomarin Pharma and administered via the Intravenous route of administration. The J Code: J1458 is aligned to the drug NAGLAZYME.

NAGLAZYME is an enzyme replacement therapy commonly used to treat Mucopolysaccharidosis IV, also known as Maroteaux-Lamy syndrome. It works by providing the patient with exogenous hydrolytic lysomomal glucosaminoglycan (GAG)-specific enzyme that is taken up into the lysosomes, allowing the body to catabolize the GAG that is built up in the organs and tissues of the patient. NAGLAZYME (J1458) is frequently used for treatment with pediatric patients. Patient assistance for this medication can be found through the BioMarin program.

ACCESS PRICING AND MORE BY REGISTERING

J1458 Added Date:

January 1, 2007

J1458 Effective Date:

January 1, 2023

J1458 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Naglazyme billing and coding information.
Naglazyme patient assistance information can be found through BioMarin RareConnections at the URL: https://www.biomarin-rareconnections.com/
NAGLAZYME prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for NAGLAZYME. Please check back in a few weeks.